Dren Bio initiates Phase 1b trial of DR-01 for Alopecia Areata and Vitiligo
Dren Bio is conducting Phase 1b trial to evaluate the safety and efficacy of DR-01 in patients with Alopecia Areata and Vitiligo.
Asset / Drug
Drug and asset intelligence for Vitiligo with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.